What Transcranial Magnetic Stimulation (TMS) Is
TMS has been around for several decades, with the first demonstration in 1985 by British neurologist Anthony Barker, who showed that a magnetic coil held to the scalp could make a person's hand move, proving the brain could be stimulated externally and non-invasively.
The FDA cleared repetitive TMS (rTMS) for treatment-resistant depression in 2008, and additional clearances have been added since, setting it up to be a more widely utilized clinical tool in several areas of mental health.
How Transcranial Magnetic Stimulation (TMS) Works
In conditions like depression and PTSD, specific brain regions lose their healthy communication patterns with the rest of the brain, which has numerous impacts on behavior, mood, and emotional regulation. TMS is meant to help things return to working together harmoniously again.
In depression, the most relevant region is the dorsolateral prefrontal cortex (DLPFC), located toward the front and side of the brain. The DLPFC is key to mood regulation, executive function, and emotional responses, and is characteristically underactive in depression—which is why it’s targeted with TMS.
TMS positions a magnetic coil over the DLPFC to generate a brief electrical current in surrounding tissue, depolarizing local neurons and triggering them to fire. In rTMS, pulses are delivered in rapid sequences. High-frequency stimulation (5 Hz or above) is excitatory, while lower frequencies (around 1 Hz) are inhibitory, and personalized protocols need to be developed (Cao et al., 2018).
The benefit of TMS appears to depend on neuroplasticity, which is the brain's capacity to adapt in response to experiences. With enough repetition, stimulated circuits strengthen and form more reliable connections.
Researchers believe TMS also influences neurotransmitter activity (dopamine, serotonin, and glutamate levels appear to change following treatment), but the exact mechanisms aren't yet fully understood. TMS works well enough to have earned FDA clearance and a large evidence base, but neuroscientists don’t know the whole story.
Who Transcranial Magnetic Stimulation (TMS) Helps
The first clinical use for TMS was treatment-resistant depression (TRD), and the majority of those who seek it out tend to fit this category. These are people who have been through many drug trials, including various combinations, without adequate depression relief. TRD can be very frustrating with all of the trial and error in treatment.
Roughly one in three people with major depression doesn't achieve remission with their first antidepressant, and many don't with their second or third. TMS offers an intervention at the level of brain circuitry versus the neurochemistry approach of standard antidepressants.
Furthermore, it’s helpful to understand what TMS doesn't claim to do: resolve underlying sources of stress, trauma, or lifestyle factors contributing to mental health conditions. TMS works best when patients are also optimizing sleep, exercise, social connection, and stress management, taking into account their broader lifestyle habits.
Common Uses
In addition to treatment-resistant depression, the FDA has cleared TMS for OCD, anxious depression, and smoking cessation. There is also a growing body of evidence for its use in post-traumatic stress disorder (PTSD), attention-deficit hyperactivity disorder (ADHD), Parkinson's disease, chronic pain, and recovery following traumatic brain injury (TBI).
Some of these are heading toward becoming established applications; others are still experimental, though TMS can still be prescribed off-label by clinicians as deemed appropriate.
What the Evidence Supports
Major Depressive Disorder (MDD)
Major depressive disorder (MDD) is characterized by persistent low mood, loss of interest or pleasure, trouble sleeping, fatigue, and difficulty concentrating, which significantly impact daily function and quality of life.
The strongest evidence for TMS is with MDD. A consensus statement authored by seventeen clinical experts reviewed approximately 1,500 studies and 118 key publications, concluding that rTMS is both safe and effective for MDD, including in patients who had not responded to antidepressant medication (McClintock et al., 2018).
Response rates typically fall between 50 and 60 percent, with remission in roughly a third, clinically significant given that these are largely patients for whom medication has already failed. Effects typically persist for around two years, with some patients maintaining benefits longer.
Obsessive Compulsive Disorder
In OCD, the brain's cortico-striato-thalamo-cortical (CSTC) circuit (a loop connecting the parts of the brain that regulate the filtering of repetitive thoughts and urges) becomes overactive and stuck, failing to send the "good enough" signal that tells the brain a thought or action can stop.
This hyperactivity is what encourages the intrusive thoughts and compulsive behaviors characteristic of OCD. Using TMS to target the medial prefrontal cortex aims to help this overactive circuitry return to normal function.
A multicenter randomized controlled trial of 99 patients found that deep TMS targeting the medial prefrontal cortex produced a 38.1% response rate compared to 11.1% in the sham group, with effects maintained at one month (Carmi et al., 2019).
A network meta-analysis confirmed that all major rTMS protocols produced significant clinical improvements for OCD compared to sham stimulation (Steuber et al., 2023). FDA clearance for OCD followed in 2018.
Where the Evidence Is Limited
Post-Traumatic Stress Disorder (PTSD)
PTSD can develop after exposure to traumatic events, characterized by intrusive memories, hypervigilance, and avoidance behaviors driven by a dysregulation in the brain’s fear circuitry.
While there’s interest in understanding potential uses for TMS in PTSD, trials have generally been smaller, less consistent in protocol, and more variable in outcomes than the depression literature (Edinoff et al., 2022).
The rationale is sound, as the prefrontal cortex loses its ability to modulate the overactive fear response driven by the amygdala, the same circuitry TMS addresses in depression. But the evidence base isn't yet comparable.
Other Potential Uses
ADHD, chronic pain, Parkinson's disease, and TBI-related cognitive recovery are active research areas, but studies frequently involve small samples, lack rigorous sham controls, or haven't been replicated at scale.
Clinicians also still cannot reliably identify in advance which patients will respond to TMS and which won't.
Safety and Regulation
TMS has a reassuring safety profile backed by decades of use. In the United States, TMS devices are FDA-cleared (not the same as FDA-approved) for MDD, OCD, anxious depression, and smoking cessation.
Off-label use for PTSD, ADHD, and others is legal but relies on clinical judgment. TMS is also cleared across most of Europe, Canada, Australia, and Israel, though specific details differ by country.
Unlike electroconvulsive therapy (ECT), TMS doesn’t pose a risk of memory impairment, and unlike medications, it produces no weight changes, sexual dysfunction, or withdrawal effects. Side effects are typically mild and self-resolving, like:
Headache or scalp discomfort during early sessions
Neck stiffness or facial twitching during stimulation
Seizure risk, which is very small and estimated to be around 1 seizure per 30,000 sessions (Taylor et al., 2021)
Contraindications include ferromagnetic implants in or near the head, certain implanted cardiac devices, active seizure disorders, and heavy substance use. Pregnancy is evaluated case by case, and TMS is currently cleared for adults only, though evidence in younger populations is developing.
The Experience
TMS sessions are outpatient, so you drive yourself, there's no recovery period, and normal activity resumes immediately. Sessions run between 20 and 40 minutes, with a standard course of five sessions per week for four to six weeks, totaling around 30 sessions.
Prior to treatment, a clinician conducts a comprehensive evaluation and calibration to determine the appropriate stimulation intensity. During sessions, a coil placed against the scalp produces a rapid clicking or tapping sensation that some find uncomfortable initially but typically adjust to.
Most people notice improvements in mood, sleep, or motivation after the first few weeks.
Insurance coverage varies considerably, so checking with your provider early is worthwhile.
The Future of Transcranial Magnetic Stimulation (TMS)
TMS is becoming more accessible. Theta burst stimulation, which is already used clinically, turns a full therapeutic session into as little as three minutes. This matters because the traditional barrier to TMS wasn't just cost or clinical availability—it was time.
There’s also a shift toward more personalization in treatments. Emerging neuroimaging research maps individual brain connectivity to identify the optimal stimulation site for each person.
PTSD trials are advancing (such as clinical trials on TMS for veterans and first responders), accelerated multi-session-per-day protocols show early promise, and longer-horizon research is underway in Alzheimer's disease, cognitive decline, and substance use disorders (Atoui et al, 2025).
Overall, TMS appears to be becoming more integrated and personalized as one component of a coordinated approach to recovery.
Takeaway
TMS is a well-evidenced, non-invasive treatment for various mental health conditions that offers genuine relief to people for whom conventional options have fallen short, and its applications are expanding.
As with any treatment, TMS works best for patients who treat it as one part of a broader commitment to their health.
